News

FDA has approved the new drug application (NDA) for Namzaric to treat moderate to severe dementia of the Alzheimer’s type in patients stabilised on memantine hydrochloride and donepezil

After securing clinical trial application (CTA) regulatory approval, the company plans to conduct a Phase I trial to assess the safety, tolerability and dose escalation of Anatabine Citrate

HOLKIRA PAK is an all-oral, short-course interferon-free treatment, with or without ribavirin (RBV) for the treatment of genotype 1 hepatitis C patients in Canada. The approval follows six

SB742457 has shown promise for patients with mild-to-moderate Alzheimer’s disease in 13 clinical studies conducted to date by GSK using more than 1,250 healthy subjects and Alzheimer’s disease

This action allows for the initiation of clinical trials, which ContraFect expects to commence in Q1 2015. Julia P. Gregory, ContraFect’s chief executive officer commented, "CF-301 will be

The FDA Orphan Drug Designation program grants a special status to drugs and biologics intended to treat, diagnose or prevent so-called orphan diseases and disorders that affect less

The company will assess the efficacy and tolerability of tipifarnib as a potential new therapy for patients infected with Hepatitis Delta Virus (HDV). The Eiger BioPharmaceuticals subsidiary is

Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology. The agreement includes a guaranty with

Under the terms of agreement, Ariad will lead the completion of the Japanese new drug application (NDA) for Iclusig, while Otsuka will file the NDA for regulatory approval